CLINICAL TRIALS PROFILE FOR IMEXON
✉ Email this page to a colleague
Clinical Trials for Imexon
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00327223 ↗ | Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy | Completed | AmpliMed Corporation | Phase 1 | AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule. |
| NCT00327249 ↗ | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | Completed | AmpliMed Corporation | Phase 1/Phase 2 | AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma |
| NCT00327288 ↗ | Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | Completed | AmpliMed Corporation | Phase 1 | Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine the highest dose of imexon which can be given with a full dose of docetaxel, and to provide information to enable the design of a future study focused on one or more specific cancer types. |
| NCT00327327 ↗ | Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma | Completed | AmpliMed Corporation | Phase 1 | AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together. |
| NCT00327600 ↗ | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma | Completed | AmpliMed Corporation | Phase 1/Phase 2 | AMP-005 is a Phase 1b/2 clinical trial designed to evaluate whether the new drug, imexon, can be administered in combination with the approved drug, dacarbazine (DTIC), for the treatment of patients with stage III or IV inoperable melanoma. The Phase 1b part of the study is designed to determine whether the two drugs can be safely combined together, and the Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether adding imexon to DTIC can improve the outcome for melanoma patients versus the findings from prior clinical studies of DTIC alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Imexon
Condition Name
Clinical Trial Locations for Imexon
Trials by Country
Clinical Trial Progress for Imexon
Clinical Trial Phase
Clinical Trial Sponsors for Imexon
Sponsor Name
